Last updated: 07/17/2024 15:06:57
Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome
EudraCT ID
EU CT Number
Not applicable
Trial status
Terminated (halted prematurely)
Terminated (halted prematurely)
Trial overview
Official title: An open label extension study to evaluate safety and efficacy of mepolizumab in patients with hypereosinophilic syndromes
Trial description: This is an open label study of mepolizumab 750 mg intravenous in those subjects who participated in study 100185 to evaluate the long term safety and efficacy of mepolizumab in subjects with hypereosinophilic syndrome. The study will also evaluate the optimal dosing frequency for clinical use, the effects on corticosteroid reduction, and decrease of signs and symptoms of Hypereosinophilic Syndrome.
Primary purpose:
Treatment
Trial design:
Single Group Assignment
Masking:
None (Open Label)
Allocation:
Not applicable
Primary outcomes:
Number of participants with any Adverse Event (AE) during the Treatment Phase
Timeframe: From the first dose of study medication up to 7 days after the last dose (up to approximately 6 years)
Number of participants with any Adverse Event (AE) during the Follow-up Phase
Timeframe: From end of Treatment Phase up to 97 days after the last dose date (up to approximately 6 years)
Secondary outcomes:
Number of participants achieving a prednisone level of =<10 mg (as sole background therapy) at the end of study
Timeframe: up to approximately 6 years
Number of participants achieving an eosinophil level of < 600 cell/microliter (uL) (in addition to the lowest background therapy) at the end of study
Timeframe: up to approximately 6 years
For those participants who completed 9 months of dosing in study MHE100185 and achieved a prednisone level <=10 mg: Number of participants achieving <= 10 mg prednisone (as sole background therapy) for >= 3months
Timeframe: up to approximately 6 years
For those participants who completed 9 months of dosing in study MHE100185 and achieved a prednisone level >10 mg: Number of participants achieving <=10 mg prednisone (as sole background therapy) for >= 8 weeks
Timeframe: up to approximately 6 years
For those participants who entered Stage 2 from study MHE100185 with a prednisone level of <=10 mg prednisone: Number of participants achieving a prednisone dose <=10 mg (as sole background therapy) for >=3 months;
Timeframe: up to approximately 6 years
For those participants who entered Stage 1 from study MHE100185 with >10 mg prednisone: Number of participants achieving a prednisone dose <=10 mg (as sole background therapy) for>=3 months
Timeframe: up to approximately 6 years
Blood eosinophil count (with consideration of the HES background therapy) during Stages 1-3
Timeframe: up to approximately 6 years
Number of participants by dosing frequency groups (defined as two week dosing ranges greater than a 4 week interval) at the end of Stage 2
Timeframe: up to approximately 6 years
Change from Baseline in the pruritus visual analogue scale (pVAS) 3 months after the start of study MHE100901 and every 6 months thereafter
Timeframe: Baseline and up to approximately 6 years
Change from Baseline in erythema/edema score 3 months after the start of study MHE100901 and every 6 months thereafter
Timeframe: Baseline and up to approximately 6 years
Change from Baseline in quality of life (QoL) and current health status: physical summary score of the study Short Form Health Survey (SF-12) 3 months after the start of study MHE100901 and every 6 months thereafter
Timeframe: Baseline and up to approximately 6 years
Change from Baseline in QoL and current health status: mental summary score of the SF12 3 months after the start of study MHE100901 and every 6 months thereafter
Timeframe: Baseline and up to approximately 6 years
Interventions:
Drug: mepolizumab
Enrollment:
78
Observational study model:
Not applicable
Primary completion date:
2010-29-09
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Hypereosinophilic Syndrome
Product
mepolizumab
Collaborators
Not applicable
Study date(s)
September 2004 to September 2010
Type
Interventional
Phase
3
Participation criteria
Sex
Female & Male
Age
18 - 75 years
Accepts healthy volunteers
No
- Signed informed consent.
- Subjects who have participated in Study MHE100185 and have been administered at least 2 doses of study medication.
- Has developed life-threatening or other serious illness or clinical manifestation deemed inappropriate for inclusion in study per the principal investigator
- Has any of the following abnormal laboratory values at the Week36/EW Visit of Study MHE100185: • Serum creatinine ≥3 times institutional upper limit normal (ULN); • AST or/ALT ≥5 times institutional ULN; • Platelet count < 50,000/uL
Inclusion and exclusion criteria
Inclusion criteria:
- Signed informed consent.
- Subjects who have participated in Study MHE100185 and have been administered at least 2 doses of study medication.
- Not pregnant or nursing
- Of non-childbearing potential (i.e., women who had a hysterectomy, are post-menopausal which is defined as 1 year without menses, have both ovaries surgically removed, or have current documented tubule ligation); or
- Of childbearing potential (i.e., women with functional ovaries and no documented impairment of oviductal or uterine function that would cause sterility). This category includes women with oligomenorrhoea [even severe], women who are perimenopausal or have just begun to menstruate. These women must have a negative serum pregnancy test at the Screening Visit, and agree to one of the following:1). Complete abstinence from intercourse from 2 weeks prior to administration of the first dose of investigational product until 3 months after the last dose of investigational product; Or 2). Consistent and correct use of one of the following acceptable methods of birth control for one month prior to the start of the investigation product and three months after the last dose:Male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for the female subjects; Implants of levonorgestrel;Injectable progestogen;Any intrauterine device (IUD) with a documented failure rate of less than 1% per year; Oral contraceptives (either combined or progestogen only)
Exclusion criteria:
- Has developed life-threatening or other serious illness or clinical manifestation deemed inappropriate for inclusion in study per the principal investigator
- Serum creatinine ≥3 times institutional upper limit normal (ULN);
- AST or/ALT ≥5 times institutional ULN;
- Platelet count < 50,000/uL
- Left ventricular ejection fraction (LVEF) < 20%;
- NYHA class IIIb or IV;
- Angina or acute myocardial infarction
- Has developed allergic reaction to Study MHE100185 investigational product Use of an investigational drug as concurrent medication
- Does not complete Week36/EW Visit assessments required in Study MHE100185
- Has completed or been terminated from Study MHE100185 for more than 1 month
- Recent history or suspicion of current drug abuse or alcohol abuse within the last 6 months
- Positive pregnancy test at the Week36/EW Visit of Study MHE100185
Has any of the following abnormal laboratory values at the Week36/EW Visit of Study MHE100185:
Has developed abnormal cardiac functions, as the following, within past 3 months:
Trial location(s)
Location
GSK Investigational Site
Boston, Massachusetts, United States, 02215
Status
Study Complete
Location
GSK Investigational Site
Cincinnati, Ohio, United States, 45229
Status
Study Complete
Location
GSK Investigational Site
Richmond, Virginia, United States, 23298
Status
Study Complete
Location
GSK Investigational Site
Bad Bramstedt, Schleswig-Holstein, Germany, 24576
Status
Study Complete
Location
GSK Investigational Site
Madison, Wisconsin, United States, 53705
Status
Study Complete
Location
GSK Investigational Site
St Leonards, New South Wales, Australia, 2065
Status
Study Complete
Location
GSK Investigational Site
Rochester, Minnesota, United States, 55905
Status
Study Complete
Location
GSK Investigational Site
Hannover, Niedersachsen, Germany, 30625
Status
Study Complete
Location
GSK Investigational Site
Salt Lake City, Utah, United States, 84132
Status
Study Complete
Location
GSK Investigational Site
Bethesda, Maryland, United States, 20892
Status
Study Complete
Location
GSK Investigational Site
West Perth, Western Australia, Australia, 6005
Status
Study Complete
Location
GSK Investigational Site
Denver, Colorado, United States, 80206
Status
Study Complete
Location
GSK Investigational Site
San Diego, California, United States, 92103
Status
Study Complete
Location
GSK Investigational Site
Nashville, Tennessee, United States, 37203-1424
Status
Study Complete
Location
GSK Investigational Site
Edmonton, Alberta, Canada, T6G 1Z
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Houston, Texas, United States, 77030
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Melbourne, Victoria, Australia, 3050
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Montreal, Québec, Canada, H3A 1A
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Nashville, Tennessee, United States, 37203-
Status
Study Complete
Location
GSK Investigational Site
South Brisbane, Queensland, Australia, 4101
Status
Terminated/Withdrawn
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Terminated (halted prematurely)
Actual primary completion date
2010-29-09
Actual study completion date
2010-29-09
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website